



SHIRAZ KHAN BASAK & CO.
CHARTERED ACCOUNTANTS
(An associate firm of D. N. Gupta & Associates)

R. K. TOWER (LEVEL-10 & 6)
86, Bir Uttam C.R. Datta Road
(312, Sonargaon Road), Dhaka-1205
Tel : 88-02-9635139, 88-02-9673597
Mobile : 01552-575775, 01711-520770
01922-117370, 01757-941837
01312-501076, 01711-535885
01645-738747, 01920-719463
E-mail : shirazkhanbasak@yahoo.com
Website : www.shirazkhanbasak.bd.com

**AUDITOR'S CERTIFICATE REGARDING MONTHLY STATUS REPORT OF
UTILIZATION OF FUND AGAINST INITIAL PUBLIC OFFERING (IPO) OF
SILCO PHARMACEUTICALS LIMITED
FOR THE MONTH OF JUNE-2021**

This is to certify that SILCO PHARMACEUTICALS LIMITED has received Tk. 300,000,000 (Taka Thirty Crore) only as Initial Public Offering (IPO) proceeds through subscription from 07 March 2019 to 19 March 2019 in the separate Bank Account (Account number 1011360531186) maintaining with Eastern Bank Limited, Principal Branch, Jiban Bima Bhaban 10, Dilkusha C/A, Dhaka-1000. In line with the condition number 4, Part C of the consent letter number BSEC/CI/IPO-271/2017/97 dated: 07 February 2019 of Bangladesh Securities and Exchange Commission (BSEC), fund utilization status as on 30 June 2021 is as follows:

Sl. No.	Purpose of Utilization	Allotment as per IPO (Tk.)	Fund utilized (Taka) up to the month of May 2021	Fund utilized (Taka) for the month of June 2021	Total Utilization of Fund up to June 30, 2021	Unspent Balance (Taka)
1	Construction of new factory building in the existing vacant area	144,655,552	172,540,058	-	172,540,058	(27,884,506)
2	Purchase of New Machinery	97,356,000	73,017,000	24,339,000	97,356,000	-
3	Purchase of Delivery Van	36,310,000	36,310,000	-	36,310,000	-
4	IPO Related Expenses	21,678,448	21,363,602	-	21,363,602	314,846
	Total IPO Proceeds	300,000,000	303,230,660	24,339,000	327,569,660	(27,569,660)
5	Interest Income/ (Bank Charges)	17,365,698	253,780	17,111,918	17,365,698	(0)
	Total IPO Proceeds & Interest Income/ (Bank Charges)	317,365,698	303,484,440	41,450,918	344,935,358	(27,569,660)

No unutilized of fund as on 30 June 2021 as at Bank with Eastern Bank Limited, Principal Branch, Jiban Bima Bhaban 10, Dilkusha C/A, Dhaka-1000. (Account number 1011360531186). We have collected relevant information and required documents for all disbursements made and we have also checked and enclosed Status Report (Annexure-A) of utilization of fund prepared by management.

During the course of our certification, we have found that:

(a) the management of SILCO PHARMACEUTICALS LIMITED have paid Tk. 2,13,63,602 during the months of May 2019 for IPO expenses from the allotment as per IPO including Tk. 1,22,61,638 adjusted which were previously paid from the company's bank account.

(b) the management of SILCO PHARMACEUTICALS LIMITED deposited as FDR amount in Tk. 15,00,00,000 (Taka: Fifteen Crore) only during the months of June 2019 with Eastern Bank Limited to separate FDR Account for 6 months period with 9% interest rate per annum which is encashed during the month December 2019. The Company deposited as FDR amount in Tk.15,00,00,000 in The City Bank Ltd. (Taka: Fifteen Crore) again to separate FDR Account for 180 days with 9% interest rate per annum. This amount have encashed during the month of July 2020 and transferred to Bank Asia Ltd. The Company deposited as FDR amount in Tk.20,00,00,000 in The Bank Asia Ltd. (Taka: Twenty Crore) again to separate FDR Account for 03 Months and 01 Month with 06% and 04% interest rate per annum during the month of September 2020. The Company have encashed Tk. 20 Crore upto the month June 2021 out of Tk. 20 Crore including Tk. 1.80 Crore during the month of June 2021. No balance during the month as FDR.





SHIRAZ KHAN BASAK & CO.
CHARTERED ACCOUNTANTS
(An associate firm of D. N. Gupta & Associates)

R. K. TOWER (LEVEL-10 & 6)
86, Bir Uttam C.R. Datta Road
(312, Sonargaon Road), Dhaka-1205
Tel : 88-02-9635139, 88-02-9673597
Mobile : 01552-575775, 01711-520770
01922-117370, 01757-941837
01312-501076, 01711-535885
01645-738747, 01920-719463
E-mail : shirazkhanbasak@yahoo.com
Website : www.shirazkhanbasak.bd.com


- (c) the management of SILCO PHARMACEUTICALS LIMITED have received as interest (IPO Accounts) amounting Tk. 22,95,412.79 net off withholding tax upto the June 2020 and Tk. 708,609.79 during the month of June 2020 and adjusted Tk. 36,744.93 by the Bank as TDS due to submission of TIN not yet.
- (d) The management of SILCO PHARMACEUTICALS LIMITED have paid Tk. 3,65,11,200 during the month of July 2019 to big Automobiles for purchase of Delivery Van (12 No. of Van with defferent model) from the allotment as per IPO and excess Tk. 2,01,200 paid to cash and adjusted with interest income.
- (e) The management of SILCO PHARMACEUTICALS LIMITED have transfered Tk. 2,50,00,000 (Pay Order No.1732748 Date: 09 January 2020) during the month of January 2020 to Company's own Bank Account (CD A/C No.3115111005507, Prime Bank Ltd. IBB Amberkhana Branch) for opening Letter of Credit for purchase of new machinery from the allotment as per IPO and the amount have included in the total unutilized fund.
- (f) the management of SILCO PHARMACEUTICALS LIMITED have received as interest (FDR Accounts) amounting Tk. 15,070,285 net off with holding tax upto the month of June 2021 and Tk. 560,743 during the month of June 2021 and adjusted with excess amount which was paid 'Construction of new factory building in the existing vacant area' previously
- (g) The management of SILCO PHARMACEUTICALS LIMITED have transfered Tk. 3,92,00,000 and 3,08,30,000 (Pay Order No.1732748 and 1809511 Date: 06 April 2020 and 9 July 2020) during the month of April and July 2020 respectively to Company's IPO Liaison Bank Account (CD A/C No.01036000766, Bank Asia Ltd. Shylet Main Branch) and the amount have included in the total unutilized fund.
- h) The company opened Letter of Credit (L/C No. 0000182120010015) of Prime Bank Ltd and paid Tk.670,000 against said L/C during the month of March 2020 which was reporting during the month of April 2020 and which was canceled and adjusted.
- i) The management of SILCO PHARMACEUTICALS LIMITED have paid Tk. 172,540,058 upto the month of March 2021 and Tk. 59,549,287 during the month of March 2021 for Construction of new factory building in the existing vacant area from the allotment as per IPO and excess amount paid to from company's own source or intrest income.
- j) The management of SILCO PHARMACEUTICALS LIMITED have paid Tk. 4,86,78,000 as advance upto the month of April 2021 for purchase of new machineries from the allotment as per IPO to Sigma International which is adjusted during the month of May 2021 (k).
- k) The management of SILCO PHARMACEUTICALS LIMITED have paid Tk. 97,356,000 upto the month of June 2021 including Tk. 2,43,39,000 during the month of June 2021 for purchase of new machineries from the allotment as per IPO. However as per the prospectus machineries was to be imported but the machineries that were purchased through local suppliers.

We also report that:

- i. the expenses/utilization has been made in line with the provision of Initial Public Offering (IPO) documents;
- ii. the expenses/utilization made in line with the condition 4, part C of consent letter of Initial Public Offering (IPO);
- iii. the expenses/utilization of IPO proceeds have been completed fully upto 30 June 2021 mentioned the time schedule/ implementation schedule as specified Initial Public Offering (IPO) documents. The Company extendent its IPO fund utilization time period another 06 months and approved by the shareholder in 25th Annual General Meeting (AGM);
- iv. the expenses/utilization made is accurate /for the purpose of the company as mentioned in Initial Public Offering (IPO) documents. Further mentioned that the machineries purchased during the June 2021 through local suppliers but it was to be imported.
- v. we also confirmed that: (i) expenses have been procured/incurred maintaining proper procedure as well as at a reasonable price; and (ii) books and records including vouchers in support of utilization of Initial Public Offering (IPO) proceeds are found correct.

Dated: 17 July 2021
Place: Dhaka




Ramendra Nath Basak, FCA
Partner
Shiraz Khan Basak & Co.
Chartered Accountants

Report on Utilization of IPO Proceeds for the month of June 2021

Name of the Company : SILCO PHARMACEUTICALS LIMITED
 Amount (BDT) of Capital Raised Through IPO : BDT. 300,000,000.00
 Date of Close of Subscription : March 19, 2019
 Proceeds Receiving Date : April 15, 2019
 Last Date of Full Utilization of Fund as per Proceeds : December 14, 2020 (within 20 Months of obtaining IPO proceeds)

Sl. No.	Purpose Mentioned in the Prospectus	Time line as per prospectus	Amount as per prospectus	Status of Utilization				Un-utilized %	Remarks
				Fund utilization (Taka) up to the month of May 2021	Fund utilized (Taka) for the month of June, 2021	Total Utilized Amount	Utilized %		
1	Construction of new factory building in the existing vacant area	18 Months	144,655,552	172,540,058	-	172,540,058	119.28%	(27,884,506)	-19%
2	Import of new Machinery	20 Months	97,356,000	73,017,000	24,339,000	97,356,000	100.00%	-	0%
3	Purchase of Delivery Van	03 Months	36,310,000	36,310,000	-	36,310,000	100%	-	0%
4	IPO Related Expenses	As or when required	21,678,448	21,363,602	-	21,363,602	98.55%	314,846	0.00%
Total IPO Proceeds			300,000,000	303,230,660	24,339,000	327,569,660		(27,569,660)	

Note:

- * BDT 46,700 has been charged by the bank as maintenance fee and others of IPO proceeds accounts (A/C No. 1011360531186 maintaining with Eastern Bank Limited) upto the month of December 2020 and Tk. 6,000 (FDR Accounts) during the month of December.
- * Balance as at Bank as on 30 June 2021 with Eastern Bank Limited, Principal Branch, Jiban Bima Bhaban 10, Dilkusha C/A, Dhaka-1000. (Account number 1011360531186) BDT 15,124.67 (this amount will be adjusted with construction of new factory building and Excess amount of IPO Expenses have adjusted with construction of Factory building as per decision by the board of director and will be place to the shareholder in the upcoming AGM for approval), Bank Asia Ltd. BDT. Nil (FDR), Bank Asia Ltd. Balance BDT. Nil.
- * The management have received as interest (IPO Accounts) amounting Tk. 22,95,412.79 net off withholding tax upto the June 2020 and Tk. 708,609.79 during the month of June 2020 and adjusted with Tk. 36,744.93 by the bank as TDS dut to submissin of TIN not yet.
- * The management of SILCO PHARMACEUTICALS LIMITED have received as interest (FDR Accounts) amounting Tk. 15,070,285 net off with holding tax upto the month of June 2021 and Tk. 560,743 during the month of June 2021 and adjusted with excess amount which was paid 'Construction of new factory building in the existing vacant area' previously
- * The Company extend its IPO fund utilization time period another 06 months and approved by the shareholder in 25th Annual General Meeting (AGM)
- * The management of SILCO PHARMACEUTICALS LIMITED have paid excess Tk.27,884,506 upto the month of March 2021 for 'Construction of new factory building' and amount shall adjusted from own source or interest income.

সিলকো ফার্মাসিউটিক্যালস লিমিটেড

Chairman

Managing Director

Company Secretary

Chief Financial Officer



Signature of Chairman

Signature of Chief Financial Officer